Variation of bone acquisition during growth hormone treatment in children can be explained by proteomic biomarkers, bone formation markers, body composition and nutritional factors
Abstract
No abstract availableKeywords
Funding Information
- Pharmacia/Pfizer (98-0198-003)
- Swedish Research Council (7509)
- Foundation Växthuset for Children, Governmental University Hospital Grants (GBG-716831, GBG-427121, GBG 719041)
- Region Östergötland (LIO-699521)
- West Sweden Region
This publication has 40 references indexed in Scilit:
- Different thresholds of tissue-specific dose-responses to growth hormone in short prepubertal childrenBMC Endocrine Disorders, 2012
- Continuous growth reference from 24thweek of gestation to 24 months by genderBMC Pediatrics, 2008
- A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short statureProteome Science, 2008
- Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone RemodelingJournal of Bone and Mineral Research, 2005
- The ‘muscle-bone unit’ during the pubertal growth spurtBone, 2004
- Pencil-beam versus fan-beam dual-energy X-ray absorptiometry comparisons across four systems: appendicular lean soft tissueActa Diabetologica, 2003
- Monoclonal Antibodies against Tissue-Nonspecific Alkaline PhosphataseTumor Biology, 2002
- Different Responses of Bone Alkaline Phosphatase Isoforms During Recombinant Insulin-like Growth Factor-I (IGF-I) and During Growth Hormone Therapy in Adults with Growth Hormone DeficiencyJournal of Bone and Mineral Research, 1997
- Prediction of the growth response of short prepubertal children treated with growth hormoneActa Paediatrica, 1995
- On the Construction of the Infancy‐Childhood‐Puberty Growth StandardActa Paediatrica, 1989